165 related articles for article (PubMed ID: 36505826)
1. Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report.
Shin JE; An HJ; Park HS; Kim H; Shim BY
Front Oncol; 2022; 12():976450. PubMed ID: 36505826
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo.
Song J; Kobayashi Y; Asano Y; Sato A; Taniguchi H; Ui-Tei K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804932
[TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.
Wang Z; He D; Chen C; Liu X; Ke N
Front Oncol; 2021; 11():801320. PubMed ID: 35145907
[TBL] [Abstract][Full Text] [Related]
6. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
[TBL] [Abstract][Full Text] [Related]
7. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF
Fang R; Gong J; Liao Z
Front Oncol; 2023; 13():1220745. PubMed ID: 37546400
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.
Shah S; Rana T; Kancharla P; Monga D
Cancer Genomics Proteomics; 2023; 20(4):398-403. PubMed ID: 37400141
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
11. Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.
Fang R; Xu S; Gong J; Liao Z
Onco Targets Ther; 2024; 17():27-31. PubMed ID: 38283732
[TBL] [Abstract][Full Text] [Related]
12. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
13. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
14. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
15. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
18. BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.
Zhang S; Yang Z; Cheng Y; Guo X; Liu C; Wang S; Zhang L
Front Pharmacol; 2022; 13():1019217. PubMed ID: 36686670
[No Abstract] [Full Text] [Related]
19. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
[TBL] [Abstract][Full Text] [Related]
20. Trametinib: a MEK inhibitor for management of metastatic melanoma.
Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
